|
|
|
Volumn 106, Issue 6 Suppl, 1999, Pages 31-36
|
|
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ANXIOLYTIC AGENT;
FLUOXETINE;
PAROXETINE;
SEROTONIN UPTAKE INHIBITOR;
ADULT;
ANXIETY DISORDER;
DELAYED RELEASE FORMULATION;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG COMBINATION;
FEMALE;
HUMAN;
MAJOR DEPRESSION;
MALE;
PSYCHOLOGICAL RATING SCALE;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
TREATMENT OUTCOME;
ADULT;
ANTI-ANXIETY AGENTS;
ANTIDEPRESSIVE AGENTS, SECOND-GENERATION;
ANXIETY DISORDERS;
DELAYED-ACTION PREPARATIONS;
DEPRESSIVE DISORDER, MAJOR;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
FLUOXETINE;
HUMANS;
MALE;
PAROXETINE;
PSYCHIATRIC STATUS RATING SCALES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SEROTONIN UPTAKE INHIBITORS;
TREATMENT OUTCOME;
|
|
EID: 69249219219
PISSN: None
EISSN: 19419260
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (2)
|
|
References (40)
|
